Patent · US Active

Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system

US8476246B2 · kind B2 · utility

6Cited by

1References

8Claims

0Family size

Assignee

Antisense Pharma GmbH · DE

Inventors

Karl-Hermann Schlingensiepen · Bovenden, DE
Frank JASCHINSKI · Puchheim, DE
Tanja Rothammer-Hampl · Haibach, DE
Anneliese Schneider · Feldafing, DE

Key dates

Filing date	Jul 30, 2010
Grant date	Jul 2, 2013
Priority date	—
Expiry date	Jul 30, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and/or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.